Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
Open Access
- 1 January 2021
- journal article
- editorial
- Published by Taylor & Francis in OncoImmunology
- Vol. 10 (1) , 2005859
Abstract
High mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels predicts favorable outcome, echoing prior studies on neoadjuvant treatment of breast and rectal cancer in which the dynamics of HMGB1 plasma levels also have prognostic value. Hence, a therapy-induced rise in HMGB1 may be interpreted as a clinical sign of ICD and therapeutic response.Keywords
Funding Information
- Ile de France and Institut National du Cancer
- Ligue contre le Cancer (équipes labellisées, Program “Equipe labelisée LIGUE” (EL2016.LNCC)
- Agence national de la recherche
- Association pour la Recherche sur le Cancer
- Association “Le Cancer du Sein, Parlons-en!”
- Cancéropôle Ile-de-France
- Chancelerie des universités de Paris
- Fondation pour la Recherche Médicale
- Elior
- European Research Area Network on Cardiovascular Diseases
- Gustave Roussy Odyssea
- the European Union Horizon 2020 Project Oncobiome
- Fondation Carrefour
- Inca
- Inserm
- Institut Universitaire de France
- Leducq Foundation
- the LabEx Immuno-Oncology
- the RHU Torino Lumière
- The SEERAVE Foundation
- the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination
- the SIRIC Cancer Research and Personalized Medicine
This publication has 10 references indexed in Scilit:
- Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patientsStrahlentherapie und Onkologie, 2021
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell deathJournal for ImmunoTherapy of Cancer, 2020
- Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancerCancer Immunology, Immunotherapy, 2019
- Identification of pharmacological agents that induce HMGB1 releaseScientific Reports, 2017
- Immunogenic cell death in cancer and infectious diseaseNature Reviews Immunology, 2016
- Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapyCancer Medicine, 2016
- The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancerAutophagy, 2016
- Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancerAutophagy, 2015
- Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonistsCell Death & Differentiation, 2013
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007